Shares of CorMedix Inc (NASDAQ:CRMD – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $14.8571.
Several equities analysts recently weighed in on the stock. D. Boral Capital reissued a “buy” rating and issued a $14.00 target price on shares of CorMedix in a research note on Monday, April 27th. Weiss Ratings upgraded shares of CorMedix from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, May 14th. Needham & Company LLC lifted their price objective on shares of CorMedix from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, April 27th. Citizens Jmp restated a “market outperform” rating and set a $19.00 price objective on shares of CorMedix in a research note on Tuesday, April 28th. Finally, Leerink Partners upped their target price on shares of CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, April 28th.
Check Out Our Latest Research Report on CorMedix
Institutional Trading of CorMedix
CorMedix Stock Performance
Shares of NASDAQ CRMD opened at $7.87 on Monday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.74 and a current ratio of 2.97. The stock has a 50 day moving average price of $8.36 and a 200 day moving average price of $7.67. The stock has a market capitalization of $617.40 million, a PE ratio of 3.69 and a beta of 1.48. CorMedix has a 52 week low of $6.13 and a 52 week high of $14.96.
CorMedix (NASDAQ:CRMD – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.08. CorMedix had a return on equity of 45.57% and a net margin of 45.25%.The firm had revenue of $127.43 million for the quarter, compared to analyst estimates of $104.96 million. During the same quarter in the previous year, the firm earned $0.30 EPS. The business’s quarterly revenue was up 226.1% on a year-over-year basis. Analysts predict that CorMedix will post 0.51 earnings per share for the current fiscal year.
CorMedix Company Profile
CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.
In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.
Featured Stories
- Five stocks we like better than CorMedix
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.
